2025 annual financial data

Lyell Immunopharma 2025 Net margin

Direct answer

Net margin was -762,355.56%.

Operating income was -203.77M USD and net income was -274.45M USD.
Operating cash flow was -150.02M USD.

Get free Lyell Immunopharma email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Revenue
36,000 USD
Operating income
-203.77M USD
Net income
-274.45M USD
Operating cash flow
-150.02M USD